Effect of time and titer in convalescent plasma therapy for COVID-19-Reference-Cited by-同舟云学术

Effect of time and titer in convalescent plasma therapy for COVID-19

Published:2021-08 Issue:8 Volume:24 Page:102898
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

de Candia Paola,Prattichizzo Francesco^ORCID,Garavelli Silvia,La Grotta Rosalba^ORCID,De Rosa Annunziata,Pontarelli Agostina,Parrella Roberto,Ceriello Antonio,Matarese Giuseppe^ORCID

Funder

Ministero della Salute

Regione Campania

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference81 articles.

1. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study;Abolghasemi;Transfus. Apher. Sci.,2020

2. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial);Agarwal;BMJ,2020

3. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease;AlQahtani;medRxiv,2020

4. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study;Alsharidah;Int. J. Infect. Dis.,2021

5. Convalescent plasma therapy in patients with COVID-19;Altuntas;Transfus. Apher. Sci.,2021

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays;Frontiers in Immunology;2023-04-25

2. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial;BMJ Open;2023-04

3. Immune Plasma for the Treatment of COVID-19: Lessons Learned so far;Hämostaseologie;2023-02

4. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial;Nature Cancer;2022-12-29

5. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients;Journal of Clinical Investigation;2022-12-15